Amphiregulin in Fibrotic Diseases and Cancer

Amphiregulin (AREG) is a significant mediator in fibrotic diseases and cancer, influencing tissue remodeling, inflammation, and fibrosis through EGFR-dependent and independent pathways. Elevated AREG levels are linked to disease severity in organs like the lungs, kidneys, liver, and heart, and it contributes to fibroblast proliferation and extracellular matrix production. Targeting AREG, particularly with therapies like SAMiRNA-AREG, has shown promise in reducing fibrosis and enhancing chemotherapy efficacy in preclinical studies, offering a precision medicine approach with minimal side effects. AREG's role in cancer includes promoting tumor progression and resistance to EGFR inhibitors, making it a promising therapeutic target. Further research is needed to validate AREG-targeting therapies and understand its complex interactions in fibrotic and cancerous conditions.